Diffuse large B-cell lymphoma: open trials in Mexico

• NCT05139017

  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC

  Medivest Centro de Investigación Integral ( Site 2704), Chihuahua City · Health Pharma Professional Research S.A. de C.V: ( Site 2700), Mexico City · Centro de Infusion Superare ( Site 2701), Mexico City

  Registry updated 2026-11-03

• NCT06717347

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Health Pharma Professional Research S.A. de C.V. ( Site 0801), Mexico City · Centro de Infusion Superare ( Site 0804), Mexico City · Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"" ( Site 0802), Monterrey · Centro de Investigacion Clinica Chapultepec ( Site 0803), Morelia · Centro de Investigacion Clinica de Oaxaca ( Site 0805), Oaxaca City · Grupo Ollin Care ( Site 0806), Pachuca · CIMAB SA de CV ( Site 0807), Torreón

  Registry updated 2026-10-21

• NCT07451652

  Low Dose Epcoritamab Plus GemOx in R/R DLBCL

  Trial Treatment · Phase 2 · Hospital Universitario Dr. Jose E. Gonzalez

  Hospital Universitario Dr. Jose Eleuterio González, Monterrey

  Registry updated 2026-04-01

• NCT06830759

  Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

  Research · AbbVie

  Hematologica Alta Especialidad /ID# 275279, Huixquilucan de Degollado · Centro de Especialidades Hemato-Oncologicas /ID# 275286, Mexico City

  Registry updated 2026-02-17

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error